Get 20% Free Customization In This Report

Buy this report from - $3456

Ocular Drug Delivery Market by Technology (Topical, Iontophoresis, Ocular Insert [Erodible and Non-Erodible], Intraocular Implants [Biodegradable and Non-Biodegradable], In Situ Gel & Punctal Plugs, and Others), Formulation Type (Liposomes & Nanoparticles, Solution, Emulsion, Suspension, and Ointment), by Disease Type (Glaucoma, Diabetic Retinopathy, Dry Eye Syndrome, Macular Degeneration, Cataract, Diabetic Macular Edema, and Others), and by End User (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, and Homecare Settings) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Medical Devices & Supplies	LI_183646	Pages: NA	Jul 2018 \| 863 Views
Author's : NA	Tables: NA	Charts: NA	Formats*:

The eye is a very valuable organ that can be affected by many diseases. These eye diseases can affect the body and the person may also lose their vision. Hence, there are many drug delivery systems available in the market to treat these eye diseases. As a result of efficient protective mechanisms of the eye, there are a few ophthalmic drugs available in the market. Almost 70% of the eye dosage formulations available in the market are in the form of eye drops and ointments. But since these drops and ointments are drained away from the ocular cavity owing to tear flow and lachrymal nasal drainage, novel and advanced pharmaceutical ophthalmic formulations are emerging in the market. These formulations are available in the form of in-situ gel, microemulsion, nanoparticle, liposome, iontophoresis, nanosuspension, and ocular inserts.

The major factors that drive the growth of the global ocular drug delivery technology market are the low bioavailability of drugs in conventional ocular therapies, increase in the incidence of glaucoma & macular degeneration, growing demand for targeted ocular drug delivery techniques, and increase in the number of approvals from government regulations for new ocular drug delivery techniques. Favorable reimbursement policies and rise in funding to develop advanced drug delivery systems can help boost the market growth. However, the solidity of the implants can lead to discomfort accompanied by drug dilution, irritation, and excessive lachrymation, which can restrain the market growth.

The global ocular drug delivery market is segmented based on technology, formulation type, disease type, end user, and geography. Based on technology, the market is categorized into topical, iontophoresis, ocular insert, intraocular implants, in situ gel & punctal plugs, and others. Ocular insert is further bifurcated into erodible and non-erodible. Intraocular implants are further divided into biodegradable and non-biodegradable. Based on formulation type, the market is categorized into liposomes & nanoparticles, solution, emulsion, suspension, and ointment. Based on disease type, the market is further segmented into glaucoma, diabetic retinopathy, dry eye syndrome, macular degeneration, cataract, diabetic macular edema, and others. Based on end-users, the market is further classified into hospitals, ophthalmic clinics, ambulatory surgical centers, and homecare settings. Based on geography, the market has been examined across North America, Europe, Asia-Pacific, and LAMEA.

Comprehensive competitive analysis and profiles of major market players such as Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., EyeGate Pharma, Clearside Biomedical, Inc., Alimera Sciences, EyeGate Pharma, Envisia Therapeutics, and Allergan, Plc. have also been provided in this report.

Key Benefits

This report provides an extensive analysis of the current and emerging market trends and dynamics in the global market.
This report entails a detailed quantitative analysis of the current market and estimations from 2017-2023, which assists in identifying prevailing market opportunities.
The projections in this report are made by analyzing the current trends and future market potential from 2017 to 2023 in terms of value.
Competitive intelligence helps understand the competitive scenario globally
An in-depth analysis of current research and clinical developments within the market has been provided with key market dynamic factors that help understand the behavior of the market.

Ocular Drug Delivery Market Key Segments:

By Technology

Topical
Iontophoresis
Ocular Insert
- Erodible
- Non-Erodible
Intraocular Implants
- Biodegradable
- Non-Biodegradable
In Situ Gel & Punctal Plugs
Others

By Formulation Type

Liposomes & Nanoparticles
Solution
Emulsion
Suspension
Ointment

By Disease Type

Glaucoma
Diabetic Retinopathy
Dry Eye Syndrome
Macular Degeneration
Cataract
Diabetic Macular Edema
Others

By End Users

Hospitals
Ophthalmic Clinics
Ambulatory Surgical Centers
Homecare Settings

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Taiwan
Rest of Asia-Pacific
LAMEA
Brazil
Turkey
Saudi Arabia
South Africa
Rest of LAMEA

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 OCULAR DRUG DELIVERY MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. TOPICAL

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. IONTOPHORESIS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. OCULAR INSERT

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
4.4.4. Erodible
4.4.5. Non-Erodible

4.5. INTRAOCULAR IMPLANTS

4.5.1. Key market trends
4.5.2. Growth factors and opportunities
4.5.3. Market size and forecast
4.5.4. Biodegradable
4.5.5. Non-Biodegradable]

4.6. IN SITU GEL & PUNCTAL PLUGS

4.6.1. Key market trends
4.6.2. Growth factors and opportunities
4.6.3. Market size and forecast

4.7. OTHERS

4.7.1. Key market trends
4.7.2. Growth factors and opportunities
4.7.3. Market size and forecast

Chapter: 5 OCULAR DRUG DELIVERY MARKET, BY FORMULATION TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LIPOSOMES & NANOPARTICLES

5.2.1. Market size and forecast

5.3. SOLUTION

5.3.1. Market size and forecast

5.4. EMULSION

5.4.1. Market size and forecast

5.5. SUSPENSION

5.5.1. Market size and forecast

5.6. OINTMENT

5.6.1. Market size and forecast

Chapter: 6 OCULAR DRUG DELIVERY MARKET, BY DISEASE TYPE

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. GLAUCOMA

6.2.1. Market size and forecast

6.3. DIABETIC RETINOPATHY

6.3.1. Market size and forecast

6.4. DRY EYE SYNDROME

6.4.1. Market size and forecast

6.5. MACULAR DEGENERATION

6.5.1. Market size and forecast

6.6. CATARACT

6.6.1. Market size and forecast

6.7. DIABETIC MACULAR EDEMA

6.7.1. Market size and forecast

6.8. OTHERS

6.8.1. Market size and forecast

Chapter: 7 OCULAR DRUG DELIVERY MARKET, BY END USERS

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. HOSPITALS

7.2.1. Market size and forecast

7.3. OPHTHALMIC CLINICS

7.3.1. Market size and forecast

7.4. AMBULATORY SURGICAL CENTERS

7.4.1. Market size and forecast

7.5. HOMECARE SETTINGS

7.5.1. Market size and forecast

Chapter: 8 OCULAR DRUG DELIVERY MARKET, BY GEOGRAPHY

8.1. OVERVIEW
8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast

8.2.4. North America Ocular Drug Delivery Market by Technology
8.2.5. North America Ocular Drug Delivery Market by Formulation Type
8.2.6. North America Ocular Drug Delivery Market by Disease Type
8.2.7. North America Ocular Drug Delivery Market by End Users

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. Germany market size and forecast
8.3.3.2. France market size and forecast
8.3.3.3. UK market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.3.4. Europe Ocular Drug Delivery Market by Technology
8.3.5. Europe Ocular Drug Delivery Market by Formulation Type
8.3.6. Europe Ocular Drug Delivery Market by Disease Type
8.3.7. Europe Ocular Drug Delivery Market by End Users

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. Australia market size and forecast
8.4.3.4. India market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Taiwan market size and forecast
8.4.3.7. Rest of Asia-Pacific market size and forecast

8.4.4. Asia-Pacific Ocular Drug Delivery Market by Technology
8.4.5. Asia-Pacific Ocular Drug Delivery Market by Formulation Type
8.4.6. Asia-Pacific Ocular Drug Delivery Market by Disease Type
8.4.7. Asia-Pacific Ocular Drug Delivery Market by End Users

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Turkey market size and forecast
8.5.3.3. Saudi Arabia market size and forecast
8.5.3.4. South Africa market size and forecast
8.5.3.5. Rest of LAMEA market size and forecast

8.5.4. LAMEA Ocular Drug Delivery Market by Technology
8.5.5. LAMEA Ocular Drug Delivery Market by Formulation Type
8.5.6. LAMEA Ocular Drug Delivery Market by Disease Type
8.5.7. LAMEA Ocular Drug Delivery Market by End Users

Chapter: 9 COMPANY PROFILES

9.1. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.

9.1.1. Operating business segments
9.1.2. Business performance
9.1.3. Key strategic moves and developments

9.2. TAIWAN LIPOSOME COMPANY, LTD.

9.2.1. Operating business segments
9.2.2. Business performance
9.2.3. Key strategic moves and developments

9.3. OCULAR THERAPEUTIX, INC.

9.3.1. Operating business segments
9.3.2. Business performance
9.3.3. Key strategic moves and developments

9.4. GRAYBUG VISION INC.

9.4.1. Operating business segments
9.4.2. Business performance
9.4.3. Key strategic moves and developments

9.5. EYEGATE PHARMA

9.5.1. Operating business segments
9.5.2. Business performance
9.5.3. Key strategic moves and developments

9.6. CLEARSIDE BIOMEDICAL, INC.

9.6.1. Operating business segments
9.6.2. Business performance
9.6.3. Key strategic moves and developments

9.7. ALIMERA SCIENCES

9.7.1. Operating business segments
9.7.2. Business performance
9.7.3. Key strategic moves and developments

9.8. EYEGATE PHARMA

9.8.1. Operating business segments
9.8.2. Business performance
9.8.3. Key strategic moves and developments

9.9. ENVISIA THERAPEUTICS

9.9.1. Operating business segments
9.9.2. Business performance
9.9.3. Key strategic moves and developments

9.10. ALLERGAN, PLC.

9.10.1. Operating business segments
9.10.2. Business performance
9.10.3. Key strategic moves and developments

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
Technologically sophisticated and reliable insights through well audited and veracious research methodology
Sovereign research proceeds that present a tangible depiction of marketplace

With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

Patent and regulatory databases for understanding of technical & legal developments
Scientific and technical writings for product information and related preemptions
Regional government and statistical databases for macro analysis
Authentic new articles, web-casts and other related releases for market evaluation
Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast

Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

Validates and improves the data quality and strengthens research proceeds
Further develops analyst team’s market understanding and expertise
Supplies authentic information about market size, share, growth and forecasts

Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

Chief executives and VPs of leading corporations specific to industry
Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)

Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

Shopping Cart is Empty..

Your Shopping Cart Is Empty